These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1536 related articles for article (PubMed ID: 23079654)
1. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Sturm D; Witt H; Hovestadt V; Khuong-Quang DA; Jones DT; Konermann C; Pfaff E; Tönjes M; Sill M; Bender S; Kool M; Zapatka M; Becker N; Zucknick M; Hielscher T; Liu XY; Fontebasso AM; Ryzhova M; Albrecht S; Jacob K; Wolter M; Ebinger M; Schuhmann MU; van Meter T; Frühwald MC; Hauch H; Pekrun A; Radlwimmer B; Niehues T; von Komorowski G; Dürken M; Kulozik AE; Madden J; Donson A; Foreman NK; Drissi R; Fouladi M; Scheurlen W; von Deimling A; Monoranu C; Roggendorf W; Herold-Mende C; Unterberg A; Kramm CM; Felsberg J; Hartmann C; Wiestler B; Wick W; Milde T; Witt O; Lindroth AM; Schwartzentruber J; Faury D; Fleming A; Zakrzewska M; Liberski PP; Zakrzewski K; Hauser P; Garami M; Klekner A; Bognar L; Morrissy S; Cavalli F; Taylor MD; van Sluis P; Koster J; Versteeg R; Volckmann R; Mikkelsen T; Aldape K; Reifenberger G; Collins VP; Majewski J; Korshunov A; Lichter P; Plass C; Jabado N; Pfister SM Cancer Cell; 2012 Oct; 22(4):425-37. PubMed ID: 23079654 [TBL] [Abstract][Full Text] [Related]
2. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation. Jha P; Pia Patric IR; Shukla S; Pathak P; Pal J; Sharma V; Thinagararanjan S; Santosh V; Suri V; Sharma MC; Arivazhagan A; Suri A; Gupta D; Somasundaram K; Sarkar C Neuro Oncol; 2014 Dec; 16(12):1607-17. PubMed ID: 24997139 [TBL] [Abstract][Full Text] [Related]
3. Distinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients. Neumann JE; Dorostkar MM; Korshunov A; Mawrin C; Koch A; Giese A; Schüller U J Neuropathol Exp Neurol; 2016 May; 75(5):408-14. PubMed ID: 26975364 [TBL] [Abstract][Full Text] [Related]
4. H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Korshunov A; Schrimpf D; Ryzhova M; Sturm D; Chavez L; Hovestadt V; Sharma T; Habel A; Burford A; Jones C; Zheludkova O; Kumirova E; Kramm CM; Golanov A; Capper D; von Deimling A; Pfister SM; Jones DTW Acta Neuropathol; 2017 Sep; 134(3):507-516. PubMed ID: 28401334 [TBL] [Abstract][Full Text] [Related]
5. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma. Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920 [TBL] [Abstract][Full Text] [Related]
6. Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM. Pathak P; Jha P; Purkait S; Sharma V; Suri V; Sharma MC; Faruq M; Suri A; Sarkar C J Neurooncol; 2015 Feb; 121(3):489-97. PubMed ID: 25479829 [TBL] [Abstract][Full Text] [Related]
7. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis. Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362 [TBL] [Abstract][Full Text] [Related]
8. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. Liu Q; Liu Y; Li W; Wang X; Sawaya R; Lang FF; Yung WK; Chen K; Fuller GN; Zhang W Acta Neuropathol; 2015 Oct; 130(4):587-97. PubMed ID: 26323991 [TBL] [Abstract][Full Text] [Related]
9. Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma. Kraus TF; Kolck G; Greiner A; Schierl K; Guibourt V; Kretzschmar HA Tumour Biol; 2015 Nov; 36(11):8439-46. PubMed ID: 26022161 [TBL] [Abstract][Full Text] [Related]
10. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas. Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887 [TBL] [Abstract][Full Text] [Related]
11. Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome. Favero F; McGranahan N; Salm M; Birkbak NJ; Sanborn JZ; Benz SC; Becq J; Peden JF; Kingsbury Z; Grocok RJ; Humphray S; Bentley D; Spencer-Dene B; Gutteridge A; Brada M; Roger S; Dietrich PY; Forshew T; Gerlinger M; Rowan A; Stamp G; Eklund AC; Szallasi Z; Swanton C Ann Oncol; 2015 May; 26(5):880-887. PubMed ID: 25732040 [TBL] [Abstract][Full Text] [Related]
12. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations. Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046 [TBL] [Abstract][Full Text] [Related]
13. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102 [TBL] [Abstract][Full Text] [Related]
14. Glioblastoma: pathology, molecular mechanisms and markers. Aldape K; Zadeh G; Mansouri S; Reifenberger G; von Deimling A Acta Neuropathol; 2015 Jun; 129(6):829-48. PubMed ID: 25943888 [TBL] [Abstract][Full Text] [Related]
15. Cerebral hemispheric glioblastoma with PNET-like morphology and histone H3.3 G34 mutation in younger patients: Report of three rare cases and diagnostic pitfalls. Cheng Y; Bao W; Wu Q Indian J Pathol Microbiol; 2020; 63(2):262-266. PubMed ID: 32317528 [TBL] [Abstract][Full Text] [Related]
16. Histone H3.3 G34 Mutations Alter Histone H3K36 and H3K27 Methylation In Cis. Shi L; Shi J; Shi X; Li W; Wen H J Mol Biol; 2018 May; 430(11):1562-1565. PubMed ID: 29689253 [TBL] [Abstract][Full Text] [Related]
17. Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma. Doll S; Urisman A; Oses-Prieto JA; Arnott D; Burlingame AL Mol Cell Proteomics; 2017 Jan; 16(1):39-56. PubMed ID: 27834733 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Venneti S; Garimella MT; Sullivan LM; Martinez D; Huse JT; Heguy A; Santi M; Thompson CB; Judkins AR Brain Pathol; 2013 Sep; 23(5):558-64. PubMed ID: 23414300 [TBL] [Abstract][Full Text] [Related]
19. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Korshunov A; Ryzhova M; Hovestadt V; Bender S; Sturm D; Capper D; Meyer J; Schrimpf D; Kool M; Northcott PA; Zheludkova O; Milde T; Witt O; Kulozik AE; Reifenberger G; Jabado N; Perry A; Lichter P; von Deimling A; Pfister SM; Jones DT Acta Neuropathol; 2015 May; 129(5):669-78. PubMed ID: 25752754 [TBL] [Abstract][Full Text] [Related]
20. A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo? Chan KM; Han J; Fang D; Gan H; Zhang Z Cell Cycle; 2013 Aug; 12(16):2546-52. PubMed ID: 23907119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]